Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

Mei Peng1,†, Yanjun Huang1,†, Ting Tao1,†, Cai-Yun Peng1,2,*, Qiongli Su1,†, Wanjun Xu1,†, Kwame Oteng Darko1, Xiaojun Tao1 & Xiaoping Yang1

EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The efficacy of gefitinib, a well-known EGFR tyrosine kinase inhibitor, combined with metformin was assessed on bladder cancer and underlying mechanisms were explored. This drug combination induced a strong anti-proliferative and anti-colony forming effect and apoptosis in bladder cancer cell lines. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt. Metformin amplified this inhibitory effect and enhanced gefitinib-induced activation of AMPK signaling pathway. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic mice confirmed the significant inhibitory effect on bladder tumor growth. These two drugs may be an excellent combination for the treatment of bladder cancer through intravesical instillation.

Bladder cancer is one of the most common cancers of the urinary tract in the world, accounting for about 74,000 new cases and 16,000 deaths in the United State in 2015.1 Although radical cystectomy with chemotherapy has been applied for treating bladder cancer patients as the standard clinical administration and exerted efficient benefits, recurrence and metastasis take place frequently.2 To prevent recurrence and progression, intravesical chemotherapy or immunosuppressive agents have been widely used after radical cystectomy.3,4 However, these supplemental methods are largely restricted with various degrees of side effects such as bone marrow suppression, allergic reactions and etc.5 Thus, there is an unmet demand to develop safe and effective administration strategy for treating bladder cancer.

Targeted therapy directed at specific molecular pathways is a promising avenue. A number of large-scale molecular studies have been conducted in bladder cancer and highlighted several potential therapeutic targets such as epidermal growth factor receptor (EGFR).6,7 EGFR pathway plays a critical role in cell proliferation, apoptosis, differentiation, migration and angiogenesis and the expression of EGFR/ERBB2 correlates with higher tumor grade/stage and poorer prognosis in bladder cancer.8,9 It has been shown that EGFR-TKI such as gefitinib is helpful for the adjuvant treatment of primary bladder cancer, however, the clinical trials suggested that it exerted modest efficacy in patients with previously treated metastasis UC(SWOG 0031).10 This may be explained by the biodiversity of the molecular signaling pathways implicated in bladder cancer pathogenesis. In general, targeting one single specific cellular pathway results in up-regulation of other pathways. Thus, targeting multiple molecular pathways may be a better option for treating cancer including bladder cancer.

Warburg effect has been proposed as one typical characteristic of tumors marked by abnormality of metabolism. There is renewed interest in developing novel anti-cancer breakthroughs modulating metabolism to limit neoplastic growth. Reversing Warburg effect might be a profound strategy for cancer treatment and is becoming a hot research area. Surprisingly, recent report has demonstrated that inhibition of EGFR signaling pathway is able to reverse this effect.11

1Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan 410013, P. R. China. 2TCM and Ethnomedicine Innovation & Development Laboratory, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P. R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to X.Y. (email: Xiaoping.Yang@hunnu.edu.cn)
At the other hand, metformin, a widely prescribed drug for treating type II diabetes, is one of the most extensively recognized metabolism modulators. It showed inhibitory effect in various cancer cell lines and xenograft cancer models and sensitized chemotherapy drugs \(^{19}\). Therefore, we hypothesize that combination of EGFR-TKI and metformin exert synergistic effect for killing bladder tumor.

In another report, we described that metformin showed significant inhibitory effect on bladder tumor growth in syngeneic orthotopic model through intravesical administration \(^{20}\). In this study, we aim to examine the effects of a combined treatment of metformin with gefitinib, a selective EGFR-TKI in bladder cancer and explore their mechanisms underlying.

**Results**

**The effects of gefitinib, alone or combined with metformin on bladder cancer cell proliferation.** To evaluate the anti-proliferative effects of different doses of gefitinib, alone and in combination with metformin, we performed a MTT assay on bladder cancer cell lines MB49, T24 and UMUC3. As shown in Table 1, IC50 values for MB49, T24 and UMUC3 are 0.75 \(\mu\)M, 25.74 \(\mu\)M, 25.90 \(\mu\)M respectively. Generally, at the range of tested concentrations, gefitinib alone didn’t show dramatic inhibitory effects. Adding metformin exhibited a profound synergistic effect as assessed by CompuSyn software (Fig. 1).

**Suppression of colony formation.** We next examined colony formation in the presence of gefitinib alone or combined with metformin. In regular continuous fashion, we found that gefitinib alone at concentration between 0 to 0.4 \(\mu\)M in MB49, 0 to 8 \(\mu\)M in T24 and UMUC3 exhibited little inhibitory effect on bladder cancer cells. However, this inhibitory effect increased when combined gefitinib with 2 mM metformin (Fig. 2A–C).

---

**Table 1.** Inhibitory concentration 50% (IC50) for gefitinib.

| Bladder cancer cell lines | Gefitinib (\(\mu\)M) |
|-------------------------|-------------------|
| MB49                    | 0.75              |
| T24                     | 25.74             |
| UMUC3                   | 25.90             |

---

**Figure 1.** Treatment with gefitinib alone or combined with metformin on cell proliferation of 3 bladder cancer cell lines. (A) Gefitinib combined with metformin inhibited MB49 proliferation synergistically. Above: Cell viability was assessed with 48 hour gefitinib at 0, 82.5, 165, 330, 660 nM alone or gefitinib combined with various concentrations (1, 2, 4 mM) of metformin treatment. Below: Combination index (CI) among the combinations of two drugs were calculated using CompuSyn software. If CI = 1, it denotes additivity; if CI > 1, it denotes antagonism; if CI < 1, it denotes synergism. CI values in the vast majority of combinations were less than 0.5, indicating moderately strong synergism. (B,C) Gefitinib combined with metformin inhibited T24 and UMUC3 proliferation synergistically. Above: Cell viability was assessed with 48 hour gefitinib at 0, 2, 4, 8, 16 \(\mu\)M alone or gefitinib combined with various concentrations (1, 2, 4 mM) of metformin treatment in T24 and UMUC3, respectively. Below: Combination index (CI) among the combinations of two drugs were calculated using CompuSyn software. If CI = 1, it denotes additivity; if CI > 1, it denotes antagonism; if CI < 1, it denotes synergism. Results are presented as the median of 5 independent experiments.
Figure 2. Evaluation of colony suppression of Gefitinib alone or combined with metformin on 3 bladder cancer cell lines. (A–C) Clonogenic assay was assessed after 7 day Gefitinib treatment alone or combined with metformin and wells were stained with crystal violet at the end of the experiment. (A) Clonogenic assay in MB49 was conducted with the treatment of 2 mM metformin, 0.4 μM Gefitinib and their combination. Above: The full view of wells were taken through stereomicroscope and images were taken through an inverted microscope with ×10 magnification. Below: the quantification of colony was determined by microplate area scan at OD 550 nm, Results are presented as the median of 5 independent experiments (*P < 0.05, #P < 0.01 vs control). (B,C) Clonogenic assay was conducted with the treatment of 2 mM metformin, 8 μM Gefitinib and their combination in T24 and UMUC3, respectively. The full view of wells and their quantification were obtained through the same method as described in MB49. Results are presented as the median of 5 independent experiments (*P < 0.05, #P < 0.01 vs control). (D–F) Colony formation assay was carried out with two hour treatment at labeled concentrations, twice per week for two weeks and stained with crystal violet at the end of the experiment. (D) Clonogenic assay in MB49 was conducted with the treatment of 25 mM metformin, 5μM Gefitinib and their combination. The full view of wells and their quantification were obtained through the same method as described in MB49. Results are presented as the median of 5 independent experiments (*P < 0.05, #P < 0.01 vs control). (E,F) Clonogenic assay was conducted with the treatment of 25 mM metformin, 100μM Gefitinib and their combination in T24 and UMUC3, respectively. The full view of wells and their quantification were obtained through the same method as described in MB49. Results are presented as the median of 5 independent experiments (*P < 0.05, #P < 0.01 vs control).
To mimic intravesical treatment, we designed an intermittent treatment protocol with 2 hours drug incubation twice per week for two weeks. Understandably, compared with that in continuous fashion in general, much higher concentrations of these drugs are needed for inhibiting the colony formation. As shown in Fig. 2D,E, the combinations of gefitinib with metformin significantly reduced colony formation in these three bladder cancer cell lines at the indicated concentration.

Taken together, these results have demonstrated the combined use of gefitinib and metformin synergistically inhibits proliferation and colony formation of bladder cancer cells.

Effects on apoptosis by combined treatment of metformin and Gefitinib. We further asked whether the increased anti-proliferative effect induced by metformin alone and in combination with gefitinib would be the result of an increased apoptosis. Therefore, we analyzed the induction of apoptosis in MB49, T24 and UMUC3 cell lines after 24-hour treatment with metformin as single agent or in combination with gefitinib. As shown in Fig. 3, flow cytometric analysis of UMUC3 cells revealed that few gefitinib-treated cells underwent apoptosis. In contrast, combined treatment with both gefitinib and metformin significantly enhanced the apoptotic cells. Similar trends were observed in T24 and MB49 cells.

Amplification of metformin on inhibitory effect of gefitinib through inducing AMPK activation. AMPK, as an energy sensor, plays an important role in cancer cell metabolism. Another report has shown that metformin significantly activated AMPK signaling pathway in the bladder cancer cell line. To determine whether the activation of AMPK signaling pathways by metformin helped in the inhibitory effect of gefitinib, we investigated the changes of intracellular AMPK signaling pathway after the treatment of gefitinib alone or combined with metformin (Fig. 4). Western blot analysis demonstrated that gefitinib alone activated AMPK and inhibited its downstream signaling proteins such as p-P70S6K or p-4EBP1 in part (Fig. 4A–C). After combining with metformin, a more pronounced decrease of the levels of protein phosphorylation of P70S6K and 4EBP1 was seen (Fig. 4D–F). Three cell lines including MB49, UMUC3 and T24 exhibited similar fashions responding to these treatments.

Effects of gefitinib treatment alone or combined with metformin on EGFR signaling pathway. Gefitinib, a selective EGFR tyrosine kinase inhibitor, down-regulated the phosphorylation of EGFR, AKT and Erk while it exerted little effect on total protein of EGFR, AKT and Erk in MB49 (Fig. 5A–C). Another study from our group20 proved that metformin inhibited bladder cancer cell growth associated with the decrease of phosphorylated AKT and ERK which are key intracellular mediators of cell survival and proliferation signals. These data together suggest that the synergistic inhibition of metformin and gefitinib on bladder cancer cells may be dependent on both AMPK and EGFR pathways jointing at Akt and Erk. As we expected, metformin caused a slight decrease on EGFR phosphorylation while further decrease was observed after the combination of metformin with gefitinib (Fig. 5D–F). Either metformin or gefitinib decreased the levels of phosphorylation of AKT and ERK and these decreases were strongly expanded while combining metformin with gefitinib (Fig. 5D–F).
Next, we added mEGF to explore whether the synergistic growth inhibitory effects obtained by the combination of metformin and gefitinib was due to a greater extent suppression of EGFR signaling via jointing at Akt and Erk. As shown in Fig. 6A–C, phosphorylation of Erk and AKT increased after mEGF stimulation. Either metformin or gefitinib treatment alone reduced these increases with further reduction while combining these two drugs together. These results demonstrated that combinations of metformin with gefitinib inhibited tumor cells growth through reducing phosphorylation of AKT and ERK synergistically.

Effects of combination of metformin and gefitinib intravesically on syngeneic orthotopic bladder cancer mice. Orthotopic mouse model was established to provide the useful tool to determine the effect of intravesical localized treatment. Syngeinic tumor implantation provided better tumor take rate compared to the xenograft implantation.
A total of five groups were designed: I-control with tumor and V-control without tumor, and 3 intravesical treatment groups: II-metformin-treated group (60 mM, 50 μL, equivalent to 19.5 mg/kg, twice per week), III-gefitinib treated group (250 μM, 50 μL, twice per week), and IV-combinations of metformin with gefitinib treated group (metformin 60 mM, Gefitinib 250 μM, twice per week). All treatments started at day 2 post tumor implantation for two weeks. Orthotopic bladder cancer implantation was processed for mice in Groups I, II, III, and IV except Group V, control mice without treatment in the absence of tumor. Figure 7A shows cumulative survival curves of five groups. Cancer cell implantation induces death of mice (Group I) but intravesical treatment of metformin with gefitinib dramatically enhanced life span with better survival (Group IV vs Group I, p = 0.003). (Group II vs Group I, p = 0.018; group III vs group I, p = 0.016). Treatment with either metformin or gefitinib alone improved mice survival respectively. As we demonstrated, decrease of mouse body weight could
be a surrogate for tumor progression. Figure 7B demonstrated the decrease of body weight in Group I, indicating the toxicity induced by tumor implantation as we expected. This decrease in body weight is attenuated by intravesical treatment with metformin or gefitinib (Groups II and III) and the combination of metformin and gefitinib is able to reverse this decrease. At the end of experiment, the weight of bladders was examined. The bladder weights in Group I were much bigger than these in Group V, indicating 100% existence of tumors in all mice in Group I (Fig. 7C).

Intravesical treatment with Gefitinib or metformin alone profoundly diminished bladder weights and the bladder weights with combination of metformin and gefitinib are almost back to normal (Group IV vs Group V, $p = 0.058$). Furthermore, H&E results show the complete absence of tumor in Group IV (Fig. 7D) and the results of Ki67 staining demonstrates similar efficiency pattern. All together, intravesical treatment of combined drugs exhibits potent anti-cancer effect.

During our experiment, no obvious side effects such as vomiting, gastrointestinal or hematuria were observed in all drug-treated groups although we saw hematuria in group I.

Discussion

In this study, we report pre-clinical results of intravesical treatment with metformin, gefitinib alone and the combination of these two drugs using a syngeneic orthotopic bladder cancer model.

Bladder cancer, one of the most common urinary tract cancer, frequently overexpresses EGFR on the luminal surface, whereas such expression is uncommon on the normal urothelium. Therefore, it is an available choice to target EGFR for the management of bladder cancer. However, there are no targeted agents approved by FDA so far, in spite of a large scale of studies focused on EGFR has been conducted. The main obstacle is the high biodiversity of bladder cancer and targeting a specific pathway usually causes “cross talk”, in which the neoplastic cells use as a secondary growth pathway.

Metformin, a widely used anti-diabetic drug now draws much attention since its anti-tumor activity in vitro and in vivo. The basis of molecular mechanism of anticancer of metformin is activation of AMPK, which is closely associated with tumor cells metabolism. Advances in cancer metabolism research increased the clinical interest to target aberrant metabolic pathways for treatment of malignant tumors.

We combined metformin with Gefitinib, attempting to suppress bladder cancer through targeting metabolism and EGFR signaling pathway. Our in vitro results showed that the combinations of metformin and gefitinib induced strong inhibition on bladder cancer cells proliferation and colony formation synergistically. The apoptosis assay further confirmed the synergistic inhibitory effect on these three bladder cancer cell lines. The main mechanisms of gefitinib are the activation of AMPK signaling pathway interfered with tumor cells metabolism and inhibition on the EGFR signaling pathway significantly. Metformin, an AMPK activator, decreased the phosphorylation of AKT, ERK at the same time and showed little effect on total AKT or ERK. Although other studies observed the increased phosphorylation of ERK, our results here demonstrated the decreased phosphorylation of ERK which is the most accepted concept with consistent observations. This may be due to the difference of cell types.

Figure 6. Effects on the protein of EGFR, AKT and ERK with the stimulation of mEGF or hEGF. Western blotting of p-EGFR, t-EGFR, p-AKT, p-ERK, t-AKT and t-ERK after the stimulation of mEGF or hEGF were done. β-actin was included as a loading control. The ratio of different proteins to β-actin was calculated by the band density of Western blots using ImageJ software. Results are presented as the median of 3 independent experiments ($* P < 0.05$, $\# P < 0.01$).
In brief, metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk and the result were further confirmed through activating EGFR signaling using mEGF.

Finally, we evaluated antitumor effect of the combination of these two drugs in syngeneic orthotopic mouse model through intravesical administration. In vivo experiments showed similar results to those obtained in vitro without evident toxicity in animals, suggesting that the combination of metformin with gefitinib may be a potential strategy for the treatment of bladder cancer.

Material and Methods

Reagents. Metformin (1,1-dimethylbiguanide hydrochloride) and gefitinib were purchased from Aladdin chemistry Co. Ltd and Selleck-Biotool Co. Ltd, respectively. Metformin was diluted across a range of concentrations in culture media and gefitinib was dissolved in DMSO to prepare the stock solution of 5 mM. Antibodies for the protein characteristics were against total EGFR, phosphor-EGFR, total Akt, phosphor-Akt(Ser473), total Erk1/2, phosphor-Erk1/2, phosphor-Acetyl-CoA Carboxylase (Ser79), phosphor-p70 S6 kinase(Thr389), phosphor-AMPKα(Thr172) and β actin (Cell Signaling, Beverly, MA, USA) and they were purchased from Cell

Figure 7. Bladders of female C57/BL6 mice were orthotopically implanted with MB49 cells (1.2 × 10^5) and divided into 4 groups randomly (n = 12 each group). Orthotopic bladder cancer implantation was processed for mice in groups I, II, III, and IV. Group V was mice without treatment without cancer cell implantation. Groups I, II and III were treated with 0.5% DMSO, 60 mM metformin and 250 μM gefitinib intravesically, respectively. Groups IV were intravesically treated with 50 μl both 60 mM metformin and 250 μM gefitinib, starting at day 2, twice per week for two weeks. (A) Kaplan-Meier survival analysis of five groups. Death of mice was checked daily and cumulative survival rate was plotted against the time course. The weight of mice was measured daily (B) and all living mice were sacrificed at day 28. (C) Weights of mouse bladders including those died before the end of experiment were measured. All bladder tissues were collected and fixed. Histological sections from these tissues were subjected to H&E stain or immunohistochemistry for Ki67 to confirm the presence or absence of tumors (D,E).
Signaling Technology. Apoptosis Detection kit (FITC Annexin V) was purchased from BD Pharmingen (San Diego, California, USA).

**Cell lines and culture conditions.** Murine and human bladder cancer cell lines provided by Dr. P Guo were cultured in DMEM supplemented (HyClone, Logan, UT, USA) with 10% of FBS (HyClone, Logan, UT, USA) and 1% of penicillin-streptomycin at 37 °C, in humidified air containing 5% of CO₂.

**Cell Viability and cologenic Assay.** Cell viability was assessed using a tetrazolium-based assay using microplate reader (Biotek, SYNERGY HTX, Vermont, USA). IC₅₀ values were determined through the dose-response curves.

Cologenic survival was defined as the ability of the cells to form colonies. Images were taken and analyzed by microscopy (Leica, DFC450C, Wetzlar, Germany) and microplate reader (Biotek, SYNERGY HTX, Vermont, USA).

**Assessment of apoptosis.** Apoptosis was detected by flow cytometry via the examination of altered plasma membrane phospholipid packing by lipophilic dye Annexin V. Briefly, treated cells were harvested by trypsin, washed twice with PBS, and then resuspended in binding buffer at a concentration of 1 × 10⁶ cells/mL according to the manufacturer's instruction. Thereafter, 5 μL of Annexin V-FITC and 5 μL of propidium iodide were added into 100 μL of cell suspension and incubated for 30 minutes at room temperature in the dark. After adding 400 μL of binding buffer, labeled cells were counted by flow cytometry within 30 minutes. All early apoptotic cells (Annexin V-positive, propidium iodide-negative), necrotic/late apoptotic cells (double positive), as well as living cells (double negative) were detected by FACSCalibur flow cytometer and subsequently analyzed by Cell Quest software (Becton Dickinson). Argon laser excitation wavelength was 488 nm, whereas emission data were acquired at wavelength 530 nm (FL-1 channel) for fluorescein isothiocyanate (FITC) and 670 nm (FL-3 c3 channel) for propidium iodide.

**Protein characterization.** Western blot assessment was performed using regular procedure in previous work. Primary antibody was added in BSA and allowed to incubate overnight at 4°C, after washed with TBS/0.05% Tween-20 before secondary antibody was added and incubated for an additional hour at room temperature. The membrane was again washed 3 times before adding Pierce Super Signal chemiluminescent substrate (Rockford, IL, USA) and then immediately imaged on Chemi Doc (Bio-Rad, Hercules, CA, USA). The films were scanned using EPSON PERFECTION V500 PHOTO and quantified by Image J (NIH, Bethesda, MD, USA).

**Orthotopic implantation and intravesical treatment.** Exponential growth of MB49 cells were harvested and cell density in collection tube was counted by cell counter. Female mice 6 to 8 weeks of age were used for cancer cell implantation. The entire procedure of orthotopic implantation and intravesical treatment was similar to the previous published work except that catheter scratching is much harder to guarantee 100% tumor cell implantation rate.

**Histologic analysis.** Tissue processing, H&E and Ki67 staining of 7-μm tissue sections were conducted by Department of Pathology, Hunan Provincial Cancer Hospital, Changsha, Hunan, P.R. China. The slides were reviewed by a pathologist, Lei Xue. The pathology evaluation was done to confirm the presence or absence of tumor.

**Statistical analysis.** All data are presented as mean ± SEM. Statistical analyses were carried out using t test and statistical significance was assumed at a value of p < 0.05.

**References**

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. *A Cancer Journal for Clinicians* **65**(1), 5–29 (2015).
2. Sternberg, C. N. *et al.* International consultation on urologic Disease-European association of urology consultation on bladder cancer 2012. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. *Eur Urol.* **63**(1), 58–66 (2013).
3. Rouprêt, M. *et al.* European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. *Eur Urol.* **68**(5), 888–79 (2015).
4. Serretta, V. *et al.* A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. *BJU Int.* **106**, 212–217 (2010).
5. Gontero, P. *et al.* The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. *Eur Urol.* **57**, 410–429 (2010).
6. Blaveri, E. *et al.* Bladder cancer outcome and subtype classification by gene expression. *Clin Cancer Res.* **11**(11), 4044–55 (2005).
7. Dyrskjøt, L. *et al.* Gene expression signatures predicts outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. *Clin Cancer Res.* **13**(12), 3545–51 (2007).
8. Kim, W. J. *et al.* A four-gene signature predicts disease progression in muscle invasive bladder cancer. *Mol Med.* **17**(5–6), 478–85 (2011).
9. Reboissou, S. *et al.* EGFR, as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. *Sci Transl Med.* **6**(244), 24ra91 (2014).
10. Bellmunt, J., Hussain, M. & Dinney, C. P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 46, Suppl: S85–104 (2003).
11. Black, P. C., Agarwal, P. K. & Dinney, C. P. Targeted therapies in bladder cancer - an update. Urol Oncol. 25(5), 433–8 (2007).
12. MacLaine, N. J., Wood, M. D., Holder, J. C., Rees, R. W. & Southgate, J. Sensitivity of normal, paramalignant and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res. 6(1), 53–63 (2008).
13. Neal, D. E. et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65(7), 1619–25 (1990).
14. Miyamoto, H. et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urolology 55(5), 679–83 (2000).
15. Latif, Z. et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40(1), 56–63 (2004).
16. Bryan, R. T. et al. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. Br J Cancer 112(6), 1052–8 (2015).
17. Petrylak, D. P. et al. Results of the Southwest Oncology 445 Group phase II evaluation (study 50031) of ZD1839 for advanced transitional cell carcinoma of 446 the urothelium. BJU Int. 105(3), 317–21 (2010).
18. DeRosa, V. et al. Reversal of warburg effect and reactivation of oxidative phosphorylation by differential Inhibition of EGFR Signaling pathways in non-small cancer. Clin Cancer Res. 21(22), 5110–20 (2015).
19. Pollak, M. N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2(9), 778–790 (2012).
20. Peng, M. et al. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget 7(8), 9102–9117 (2016).
21. Yang, X. et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 19(1), 148–57 (2013).
22. Günther, J. H. et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Research 59(12), 2834–7 (1999).
23. Cheng, J. et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 62(14), 4157–63 (2002).
24. Sidaway, P. Bladder cancer: urinary EGFR and EpCAM predict cancer-specific survival. Nat Rev Urol. 12(4), 184 (2015).
25. Tennant, D. A., Duran, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10, 267–77 (2010).
26. Teicher, B. A., Linehan, W. M. & Helman, L. J. Targeting cancer metabolism. Clin Cancer Res. 18, 5537–45 (2012).
27. Morgillo, F. et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 19(13), 3508–19 (2013).
28. Chai, X. et al. Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep. 5, 14404 (2015).
29. Ming, M. et al. Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA Synthesis and proliferation in pancreatic cancer cells. PLoS One 9(12), e114573 (2014).
30. Hsieh, S. C., Tsai, J. P., Yang, S. F., Tang, M. J. & Hsieh, Y. H. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/INK-1B-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids 46(12), 2809–22 (2014).
31. Zhu, Y. T. et al. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer. Stem Cell Res. 13(1), 111–22 (2014).

Acknowledgements
This project was supported by Advanced Fund of Hunan Provincial Education Department (No. 15A117) and Xiaoxiang Endowed University Professor Fund of Hunan Normal University (No. 840140-008) to X.Y. All authors thank to Department of Pathology, Hunan Provincial Cancer Hospital, Changsha, Hunan, P. R. China to share the Facility of Pathology Analysis and a pathologist, Lei Xue reviewed all specimens.

Author Contributions
M.P., Y.H., T.T., C.-Y.P., W.X., Q.S. and X.T. performed all experiments and collected all data. M.P., Y.H., T.T., C.P., K.O.D., Q.S. and X.Y. analyzed the data and wrote the main manuscript text. X.Y. supervised this work. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Peng, M. et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Sci. Rep. 6, 28611; doi: 10.1038/srep28611 (2016).